Kailera Therapeutics, Inc. (KLRA) Gamma Exposure (GEX) & Greeks

Gamma exposure (GEX) analysis shows how options positioning creates dealer hedging pressure across strikes. Includes delta, vanna, charm, vomma, and vega exposure by strike price.

Kailera Therapeutics, Inc. (KLRA) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $2.84B, listed on NASDAQ, employing roughly 145 people, carrying a beta of 0.00 to the broader market. Kailera Therapeutics is a clinical-stage biopharmaceutical company developing a diverse pipeline of next-generation therapies designed to treat obesity and related conditions. Led by Ronald C. Renaud Jr., public since 2026-04-17.

Greeks exposure analysis shows dealer hedging pressure across strike prices for all six Greeks. No recent options activity for KLRA as of 2026-06-02; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.

Learn how gamma exposure is reported and how to read the data →